Top

Published in:

01-02-2014 | Topic Paper

The role of functional imaging in the era of targeted therapy of renal cell carcinoma

Authors: Margarita Braunagel, Anno Graser, Maximilian Reiser, Mike Notohamiprodjo

Published in: World Journal of Urology | Issue 1/2014

Abstract

Antiangiogenic therapies interacting with tumor-specific pathways have been established for targeted therapy of renal cell carcinoma (RCC). However, evaluation of tumor response based on morphologic tumor diameter measurements has limitations, as tumor shrinkage may lag behind pathophysiological response. Functional imaging techniques such as dynamic contrast-enhanced (DCE) ultrasound (US), computed tomography (CT) and magnetic resonance imaging (MRI), unenhanced diffusion-weighted MRI (DW-MRI), and also metabolic imaging with positron emission tomography (PET) have the ability to assess physiological parameters and to predict and monitor therapy response. Assessment of changes in vascularity, cellularity, oxygenation, and glucose uptake with functional imaging during targeted therapy may correlate with progression-free survival and can predict tumor response or progression. In this review, we explore the potential of functional imaging techniques for assessing the effects of targeted therapy of RCC and as well review the reproducibility and limitations.

Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer statistics, 2007. CA Cancer J Clin 57(1):43–66PubMedCrossRef

Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124PubMedCrossRef

Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22(1):42–60PubMed

Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039–2049PubMedCrossRef

Brugarolas J (2007) Renal-cell carcinoma–molecular pathways and therapies. N Engl J Med 356(2):185–187PubMedCrossRef

Mellado B, Gascon P (2006) Molecular biology of renal cell carcinoma. Clin Transl Oncol 8(10):706–710PubMedCrossRef

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247PubMedCrossRef

Rosen MA, Schnall MD (2007) Dynamic contrast-enhanced magnetic resonance imaging for assessing tumor vascularity and vascular effects of targeted therapies in renal cell carcinoma. Clin Cancer Res 13(2 Pt 2):770s–776sPubMedCrossRef

Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O’Dwyer PJ, Rosen MA (2013) MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 200(1):120–126PubMedCrossRef

10.

Smith AD, Shah SN, Rini BI, Lieber ML, Remer EM (2010) Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR Am J Roentgenol 194(6):1470–1478PubMedCrossRef

11.

Ratain MJ, Eckhardt SG (2004) Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol 22(22):4442–4445PubMedCrossRef

12.

Goh V, Halligan S, Taylor SA, Burling D, Bassett P, Bartram CI (2007) Differentiation between diverticulitis and colorectal cancer: quantitative CT perfusion measurements versus morphologic criteria–initial experience. Radiology 242(2):456–462PubMedCrossRef

13.

Lassau N, Chami L, Benatsou B, Peronneau P, Roche A (2007) Dynamic contrast-enhanced ultrasonography (DCE-US) with quantification of tumor perfusion: a new diagnostic tool to evaluate the early effects of antiangiogenic treatment. Eur Radiol 17(Suppl 6):F89–F98PubMedCrossRef

14.

Hudson JM, Karshafian R, Burns PN (2009) Quantification of flow using ultrasound and microbubbles: a disruption replenishment model based on physical principles. Ultrasound Med Biol 35(12):2007–2020PubMedCrossRef

15.

Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 10(3):223–232PubMedCrossRef

16.

Tognolini A, Pianykh O, Bhatt R, Goldberg SN, Atkins MB, Raptopoulos V (2008) CT perfusion in follow-up of antiangiogenic drugs in patients with renal cell carcinoma: preliminary experience. Eur Radiol 18(Suppl 1):281

17.

Michaely HJ, Sourbron SP, Buettner C, Lodemann KP, Reiser MF, Schoenberg SO (2008) Temporal constraints in renal perfusion imaging with a 2-compartment model. Invest Radiol 43(2):120–128PubMedCrossRef

18.

van der Molen AJ, Thomsen HS, Morcos SK (2004) Effect of iodinated contrast media on thyroid function in adults. Eur Radiol 14(5):902–907PubMedCrossRef

19.

Marenzi G, Cabiati A, Milazzo V, Rubino M (2012) Contrast-induced nephropathy. Intern Emerg Med 7(Suppl 3):S181–S183PubMedCrossRef

20.

Li SP, Padhani AR (2012) Tumor response assessments with diffusion and perfusion MRI. J Magn Reson Imaging 35(4):745–763PubMedCrossRef

21.

Flaherty KT, Rosen MA, Heitjan DF, Gallagher ML, Schwartz B, Schnall MD, O’Dwyer PJ (2008) Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7(4):496–501PubMedCrossRef

22.

De Bazelaire C, Rofsky NM, Duhamel G, Michaelson MD, George D, Alsop DC (2005) Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). Acad Radiol 12(3):347–357PubMedCrossRef

23.

Muehllehner G, Karp JS (2006) Positron emission tomography. Phys Med Biol 51(13):R117–R137PubMedCrossRef

24.

Schmidt GP, Haug A, Reiser MF, Rist C (2010) Whole-body MRI and FDG-PET/CT imaging diagnostics in oncology. Der Radiologe 50(4):329–338PubMedCrossRef

25.

Kang DE, White RL Jr, Zuger JH, Sasser HC, Teigland CM (2004) Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J Urol 171(5):1806–1809PubMedCrossRef

26.

Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N, Yasuda S (2002) Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol 9(1):15–18PubMedCrossRef

27.

Le Bihan D, Turner R, Douek P, Patronas N (1992) Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 159(3):591–599PubMedCrossRef

28.

Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M (1986) MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 161(2):401–407PubMed

29.

Notohamiprodjo M, Dietrich O, Horger W, Horng A, Helck AD, Herrmann KA, Reiser MF, Glaser C (2010) Diffusion tensor imaging (DTI) of the kidney at 3 tesla-feasibility, protocol evaluation and comparison to 1.5 Tesla. Invest Radiol 45(5):245–254PubMedCrossRef

30.

Notohamiprodjo M, Glaser C, Herrmann KA, Dietrich O, Attenberger UI, Reiser MF, Schoenberg SO, Michaely HJ (2008) Diffusion tensor imaging of the kidney with parallel imaging: initial clinical experience. Invest Radiol 43(10):677–685PubMedCrossRef

31.

Padhani AR, Liu G, Koh DM, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, Collins D et al (2009) Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 11(2):102–125PubMedCentralPubMed

32.

Koh DM, Blackledge M, Padhani AR, Takahara T, Kwee TC, Leach MO, Collins DJ (2012) Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls. AJR Am J Roentgenol 199(2):252–262PubMedCrossRef

33.

Sommer G, Wiese M, Winter L, Lenz C, Klarhofer M, Forrer F, Lardinois D, Bremerich J (2012) Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and (18)F-fluorodeoxyglucose-positron emission tomography/computed tomography. Eur Radiol

34.

Kim W, Kaelin WG Jr (2003) The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. Curr Opin Genet Dev 13(1):55–60PubMedCrossRef

35.

Pacheco-Torres J, Lopez-Larrubia P, Ballesteros P, Cerdan S (2010) Imaging tumor hypoxia by magnetic resonance methods. NMR Biomed

36.

Padhani A (2010) Science to practice: what does MR oxygenation imaging tell us about human breast cancer hypoxia? Radiology 254(1):1–3PubMedCrossRef

37.

Mees G, Dierckx R, Vangestel C, Van de Wiele C (2009) Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 36(10):1674–1686PubMedCentralPubMedCrossRef

38.

Baudelet C, Cron GO, Gallez B (2006) Determination of the maturity and functionality of tumor vasculature by MRI: correlation between BOLD-MRI and DCE-MRI using P792 in experimental fibrosarcoma tumors. Magn Reson Med 56(5):1041–1049PubMedCrossRef

39.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216PubMedCrossRef

40.

De Bruyne S, Van Damme N, Smeets P, Ferdinande L, Ceelen W, Mertens J, Van de Wiele C, Troisi R, Libbrecht L, Laurent S et al (2012) Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br J Cancer 106(12):1926–1933PubMedCentralPubMedCrossRef

41.

Hahn OM, Yang C, Medved M, Karczmar G, Kistner E, Karrison T, Manchen E, Mitchell M, Ratain MJ, Stadler WM (2008) Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol 26(28):4572–4578PubMedCrossRef

42.

Galbraith SM (2003) Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development. Br J Radiol 76:S83–S86PubMedCrossRef

43.

Desar IM, ter Voert EG, Hambrock T, van Asten JJ, van Spronsen DJ, Mulders PF, Heerschap A, van der Graaf WT, van Laarhoven HW, van Herpen CM (2011) Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study. Cancer Imaging 11:259–265PubMedCentralCrossRef

44.

Sharma U, Danishad KK, Seenu V, Jagannathan NR (2009) Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy. NMR Biomed 22(1):104–113PubMedCrossRef

45.

Lassau N, Koscielny S, Albiges L, Chami L, Benatsou B, Chebil M, Roche A, Escudier BJ (2010) Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography. Clin Cancer Res 16(4):1216–1225PubMedCrossRef

46.

Khandani AH, Rathmell WK (2012) Positron emission tomography in renal cell carcinoma: an imaging biomarker in development. Semin Nucl Med 42(4):221–230PubMed

47.

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, Pruim J, Price P (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773–1782PubMedCrossRef

48.

Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T et al (2012) Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer 12:162PubMedCentralPubMedCrossRef

49.

Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K et al (2011) Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res 17(18):6021–6028PubMedCrossRef

50.

Cui Y, Zhang XP, Sun YS, Tang L, Shen L (2008) Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248(3):894–900PubMedCrossRef

51.

DeVries AF, Kremser C, Hein PA, Griebel J, Krezcy A, Ofner D, Pfeiffer KP, Lukas P, Judmaier W (2003) Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int J Radiat Oncol Biol Phys 56(4):958–965PubMedCrossRef

52.

Thoeny HC, De Keyzer F, Vandecaveye V, Chen F, Sun X, Bosmans H, Hermans R, Verbeken EK, Boesch C, Marchal G et al (2005) Effect of vascular targeting agent in rat tumor model: dynamic contrast-enhanced versus diffusion-weighted MR imaging. Radiology 237(2):492–499PubMedCrossRef

53.

Koh DM, Blackledge M, Collins DJ, Padhani AR, Wallace T, Wilton B, Taylor NJ, Stirling JJ, Sinha R, Walicke P et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19(11):2728–2738PubMedCrossRef

54.

Revheim ME, Winge-Main AK, Hagen G, Fjeld JG, Fossa SD, Lilleby W (2011) Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma. Clin Oncol (R Coll Radiol) 23(5):339–343CrossRef

55.

Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet V, Itti E, Cuenod CA, Chatellier G, Oudard S et al (2011) Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month’s sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study. J Nucl Med 52(7):1048–1055PubMedCrossRef

56.

Li SP, Taylor NJ, Makris A, Ah-See ML, Beresford MJ, Stirling JJ, d’Arcy JA, Collins DJ, Padhani AR (2010) Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology 257(3):643–652PubMedCrossRef

57.

Heye T, Davenport M, Horvath J, Feuerlein S, Breault S, Bashir M, Merkle EM, Boll DT (2012) Reproducibility of dynamic contrast-enhanced MRI perfusion parameters on various computer aided diagnosis workstations: taking a peek into the black box. Proc Int Soc Magn Reson Med 20:240

58.

Bokacheva L, Rusinek H, Zhang JL, Chen Q, Lee VS (2009) Estimates of glomerular filtration rate from MR renography and tracer kinetic models. J Magn Reson Imaging 29(2):371–382PubMedCentralPubMedCrossRef

59.

Attenberger UI, Sourbron SP, Michaely HJ, Reiser MF, Schoenberg SO (2010) Retrospective respiratory triggering renal perfusion MRI. Acta Radiol 51(10):1163–1171PubMedCrossRef

60.

Patel J, Sigmund EE, Rusinek H, Oei M, Babb JS, Taouli B (2010) Diagnosis of cirrhosis with intravoxel incoherent motion diffusion MRI and dynamic contrast-enhanced MRI alone and in combination: preliminary experience. J Magn Reson Imaging 31(3):589–600PubMedCrossRef

61.

Cafagna D, Rubini G, Iuele F, Maggialetti N, Notaristefano A, Pinto D, Niccoli-Asabella A, Palmiotti G, Lasciarrea M, Maggialetti A (2012) Whole-body MR-DWIBS vs. [18F]-FDG-PET/CT in the study of malignant tumors: a retrospective study. Radiol Med 117(2):293–311PubMedCrossRef

62.

Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22(4):275–282PubMed

63.

Michaely HJ, Schoenberg SO, Oesingmann N, Ittrich C, Buhlig C, Friedrich D, Struwe A, Rieger J, Reininger C, Samtleben W et al (2006) Renal artery stenosis: functional assessment with dynamic MR perfusion measurements–feasibility study. Radiology 238(2):586–596PubMedCrossRef

64.

Dujardin M, Sourbron S, Luypaert R, Verbeelen D, Stadnik T (2005) Quantification of renal perfusion and function on a voxel-by-voxel basis: a feasibility study. Magn Reson Med 54(4):841–849PubMedCrossRef

65.

Hackstein N, Kooijman H, Tomaselli S, Rau WS (2005) Glomerular filtration rate measured using the Patlak plot technique and contrast-enhanced dynamic MRI with different amounts of gadolinium-DTPA. J Magn Reson Imaging 22(3):406–414PubMedCrossRef

66.

Sourbron SP, Michaely HJ, Reiser MF, Schoenberg SO (2008) MRI-measurement of perfusion and glomerular filtration in the human kidney with a separable compartment model. Invest Radiol 43(1):40–48PubMedCrossRef

67.

Dimitrakopoulou-Strauss A, Strauss LG, Heichel T, Wu H, Burger C, Bernd L, Ewerbeck V (2002) The role of quantitative (18)F-FDG PET studies for the differentiation of malignant and benign bone lesions. J Nucl Med 43(4):510–518PubMed

68.

Okada M, Shimono T, Komeya Y, Ando R, Kagawa Y, Katsube T, Kuwabara M, Yagyu Y, Kumano S, Imaoka I et al (2009) Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions. Ann Nucl Med 23(4):349–354PubMedCrossRef

69.

Adams MC, Turkington TG, Wilson JM, Wong TZ (2010) A systematic review of the factors affecting accuracy of SUV measurements. AJR Am J Roentgenol 195(2):310–320PubMedCrossRef

70.

Tunariu N, Kaye SB, Desouza NM (2012) Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer 106(4):619–628PubMedCentralPubMedCrossRef

71.

Notohamiprodjo M, Staehler M, Steiner N, Schwab F, Sourbron S, Michaely HJ, Reiser MF, Nikolaou K (2012) Combined diffusion-weighted-, blood oxygen level dependent- and dynamic contrast enhanced-MRI for assessment of renal cell carcinoma. ISMRM 2012, abstr 344

72.

Andriantsimiavona R, Koh DM, Collins D, Doran S, Leach MO (2012) Pathological tissue classification by multiparametric MRI: technical development and application in renal masses characterisation. Proc Int Soc Magn Reson Med 20:343

73.

Clevert DA, D’Anastasi M, Jung EM (2013) Contrast-enhanced ultrasound and microcirculation: efficiency through dynamics–current developments. Clin Hemorheol Microcirc 53(1–2):171–186PubMed

74.

Attenberger UI, Sourbron SP, Notohamiprodjo M, Lodemann KP, Glaser CG, Reiser MF, Schoenberg SO, Michaely HJ (2008) MR-based semi-automated quantification of renal functional parameters with a two-compartment model: an interobserver analysis. Eur J Radiol 65(1):56–65CrossRef

75.

Notohamiprodjo M, M. P, Glaser C, Helck AD, Lodemann KP, Jespersen B, Fischereder M, Reiser MF, Sourbron SP (2011) Comparison of Gd-DTPA and Gd-BOPTA for studying renal perfusion and filtration. J Magn Reson Imaging

76.

Braunagel M, Radler E, Ingrisch M, Staehler M, Nikolaou K, Reiser MF, Notohamiprodjo M (2012) Perfusion and Permeability DCE-MRI measurements in renal cell carcinoma and metastases: effect of ROI size and positioning on inter- and intraobserver variability. ESMRMB 2012, abstr 183

77.

Fournier LS, Oudard S, Thiam R, Trinquart L, Banu E, Medioni J, Balvay D, Chatellier G, Frija G, Cuenod CA (2010) Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology 256(2):511–518PubMedCrossRef

78.

Goh V, Halligan S, Gartner L, Bassett P, Bartram CI (2006) Quantitative colorectal cancer perfusion measurement by multidetector-row CT: does greater tumour coverage improve measurement reproducibility? Br J Radiol 79(943):578–583PubMedCrossRef

79.

Galbraith SM, Lodge MA, Taylor NJ, Rustin GJ, Bentzen S, Stirling JJ, Padhani AR (2002) Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis. NMR Biomed 15(2):132–142PubMedCrossRef

80.

Lambregts DM, Beets GL, Maas M, Curvo-Semedo L, Kessels AG, Thywissen T, Beets-Tan RG (2011) Tumour ADC measurements in rectal cancer: effect of ROI methods on ADC values and interobserver variability. Eur Radiol 21(12):2567–2574PubMedCentralPubMedCrossRef

81.

Westerterp M, Pruim J, Oyen W, Hoekstra O, Paans A, Visser E, van Lanschot J, Sloof G, Boellaard R (2007) Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. Eur J Nucl Med Mol Imaging 34(3):392–404PubMedCrossRef

82.

de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, Boers M, Smit EF, Stroobants S, Weber WA et al (2012) Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med 53(5):701–708PubMedCrossRef

83.

Pedrosa I, Alsop DC, Rofsky NM (2009) Magnetic resonance imaging as a biomarker in renal cell carcinoma. Cancer 115(10 Suppl):2334–2345PubMedCrossRef

Title: The role of functional imaging in the era of targeted therapy of renal cell carcinoma
Authors: Margarita Braunagel
Anno Graser
Maximilian Reiser
Mike Notohamiprodjo
Publication date: 01-02-2014
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 1/2014
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-013-1074-7

At a glance: The STEP trials

Springer Medicine

The role of functional imaging in the era of targeted therapy of renal cell carcinoma

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2014

Peripelvic/periureteral fat invasion is independently associated with worse prognosis in pT3 upper tract urothelial carcinoma

Time to say good bye to shockwave lithotripsy?

Estrogen receptor β (ERβ) is a novel prognostic marker of recurrence survival in non-muscle-invasive bladder cancer potentially by inhibiting cadherin switch

Lichen sclerosus in men is associated with elevated body mass index, diabetes mellitus, coronary artery disease and smoking

Systemic therapy of renal cell carcinoma

How far is the horizon? From current targets to future drugs in advanced renal cancer